The third and fourth sentences of the Results sub-section of the Abstract are incorrect. The correct sentences should read: In cART-treated patients 10-fold higher HIV RNA was associated with 15% higher suPAR, whereas there was no association in untreated patients. Patients with CD4+ cell count \<350 cells/μL had higher suPAR levels than patients with CD4+ cell count ≥350 cells/μL, though not significantly. We found no association with nadir CD4+ cell count or with duration of HIV-infection.

The second to last sentence of the Results sub-section of the Abstract is incorrect. The correct sentence should read: Finally, suPAR was not associated with adipose tissue distribution, but strongly associated with low leg muscle mass.

The last sentence of the Results sub-section of the Abstract is incorrect. The correct sentence should read: In patients infected through intravenous drug use (IDU), CD4+ cell counts ≥350 cells/μL were associated with 27% lower suPAR (p  =  0.03), and suPAR was 4% lower pr. year during treatment (p  =  0.05); however, there was no association with HIV RNA, duration of HIV-infection, nor cART.

The last sentence of the second paragraph of the "Impact of HIV-related Factors on suPAR levels" sub-section of the Results is incorrect. The correct sentence should read: Patients with CD4+ cell counts \<350 cells/μL had 6% higher suPAR levels (p = 0.09) than patients with higher CD4+ cell counts in multiple analyses.

The third paragraph of the "Impact of HIV-related Factors on suPAR levels" sub-section of the Results is incorrect. The correct sentence should read: A 10-fold higher VL was associated with 15% higher suPAR levels (p\<0.001) in cART-treated patients, but not in untreated patients (estimate = 2%, p = 0.60), when adjusted for sex, age, European descent, duration of HIV-infection, nadir CD4+ cell counts, and CD4+ cell counts, see [Figure 2](#pone-0094152-g001){ref-type="fig"} and [Table 2](#pone-0094152-t002){ref-type="table"}.

![The association of suPAR and viral load according to treatment status.\
The figure represents a scatter plot of the association between suPAR and viral load. Circles represent cART-treated patients (N = 795); boxes represent non cART-treated patients (N = 150). The regression line for cART-treated patients is continuous; the regression line for non-cART treated patients is dashed. The lower level of detection of HIV RNA in this study was 39 copies/mL. **Abbreviations:** cART: Combination antiretroviral treatment; suPAR: soluble urokinase plasminogen activator receptor.](pone.0094152.g001){#pone-0094152-g001}

The last sentence of the "Patients Infected through IDU" sub-section of the Results is incorrect: The correct sentence should read: Patients with CD4+ cell counts ≥350 cells/μL had 27% lower suPAR levels (p = 0.03; 95% CI:-45%, -4%) than patients with CD4+ cell counts \<350 cells/μL, and there was no significant association with VL (estimate = 5% per 10-fold increase, p = 0.57).

The second sentence of the second paragraph of the Discussion section is incorrect. The correct sentence should read: suPAR levels were 6% higher in patients with low CD4+ cell counts (\<350 cells/μL), though not significantly. We found no association of suPAR and duration of HIV-infection, nor with nadir CD4+ cell counts.

The first sentence of the third paragraph of the Discussion section is incorrect. The correct sentence should read: For every 10-Fold increase in VL, we found 15% higher suPAR levels in multiple regression analysis in cART-treated patients (p\<0.001); however, there was no significant association in patients not receiving treatment (estimate = 2%, p = 0.60), see [Figure 2](#pone-0094152-g001){ref-type="fig"}.

The first three sentences of the fifth paragraph of the Discussion section are incorrect. The sentences should read: We did not find any association with fat deposition measures or lipodystrophy by DXA scans. We have previously found increased suPAR levels in HIV-infected patients with clinician diagnosed lipodystrophy \[37\]. This divergence could reflect difficulties in assessing lipodystrophy using single DXA scans, or suPAR not being associated with lipodystrophy in this more heterogeneous patient cohort. Please note that the sentences following, "Bonnet et al. \[28\] proposed reference values to define lipodystrophy by DXA scan. Only four of 283 patients in this study had lipodystrophy when applying this definition, indicating that it is not sensitive enough," should be deleted.

The last sentence of the sixth paragraph of the Discussion section is incorrect. The sentence should read: However, we cannot exclude that the association of suPAR with low leg muscle mass is a physical activity-mediated effect.

The fourth sentence of the last paragraph of the Discussion section is incorrect. The sentence should read: However, we did not find any association with nadir CD4+ cell count, and suPAR was not significantly higher in individuals with low CD4+ cell count (\<350 cells/μL).

[Table 1](#pone-0094152-t001){ref-type="table"} contains multiple errors. Please see the corrected [Table 1](#pone-0094152-t001){ref-type="table"} here.

10.1371/journal.pone.0051698.t001

###### Baseline characteristics for HIV-infected patients not infected through intravenous drug use (IDU).

![](pone.0094152.t001){#pone-0094152-t001-1}

  Demography                            Median   Range (5%; 95% percentiles)   N total
  ------------------------------------ -------- ----------------------------- ---------
  Age (years)                            44.3            29.5; 64.2              992
  Sex (men)                             74.9%                                    992
  European descent                      76.0%                                    992
  **HIV-related Factors**                                                     
  HIV duration (years)                   9.2              0.6; 21.8              992
  Nadir CD4 (cells/μL)                   183               9; 476                959
  Nadir CD4\<200 cells/μL               55.6%                                    959
  Current cART                          84.7%                                    990
  Never cART                            13.0%                                    990
  Total treatment duration (years)       6.7              0.5; 10.8              861
  CD4\<350 cells/μL                     21.2%                                    949
  HIV RNA (copies/mL)                     39             39; 33,300              947
  HIV RNA≤40 copies mL                  72.4%                                    947
  **Lifestyle and Body Composition**                                          
  Current daily smoking                 35.1%                                    428
  Waist circumference (cm)               91.5            72.0; 110.5             415
  BMI (kg/m^2^)                          23.9            19.1; 31.7              465
  Metabolic syndrome                    30.6%                                    366

**Abbreviations:** cART: Combination antiretroviral treatment; BMI: Body mass index

[Table 2](#pone-0094152-t002){ref-type="table"} Contains multiple errors. Please see the corrected [Table 2](#pone-0094152-t002){ref-type="table"} here.

10.1371/journal.pone.0051698.t002

###### HIV- and non HIV-related factors influencing suPAR levels.
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                                                                                       Univariate       Multiple                                        
  ------------------------------------------------------------------------------- -------------------- ---------- ----- --------------------- --------- -----
  **Demography**                                                                                                                                        
  Age ≥60 vs. \<40 years                                                           20.0 (10.6; 30.2)    \<0.001    992    19.1 (9.4; 30.0)     \<0.001   992
  Age ≥60 vs. 40-50 years                                                           9.3 (1.0; 18.3)                       8.4 (0.1; 17.4 )              
  Age ≥60 vs. 50-60 years                                                           5.2 (-3.6; 14.8)                      4.7 (-4.0; 14.3)              
  Sex (men vs. women)                                                               -1.8 (-6.9; 3.7)      0.52     992   -7.1 (-12.8; -1.1)     0.02     992
  European descent                                                                  10.1 (4.4; 16.3)    \<0.001    992     9.8 (3.1; 17.0)      0.004    992
  **HIV-related**                                                                                                                                       
  HIV duration (years)                                                               0.5 (0.1; 0.8)       0.01     992     0.1 (-0.3; 0.5)      0.75     992
  Nadir CD4+ (cells/μL)[\*](#nt103){ref-type="table-fn"}                           0.01 (-0.01; 0.02)     0.44     959   -0.01 (-0.02; 0.01)    0.62     958
  No current cART[\*](#nt103){ref-type="table-fn"}                                  9.0 (2.2; 16.2)      0.009     990     17.3 (8.0;27.4)     \<0.001   958
  Treatment duration (years)[\*\*](#nt104){ref-type="table-fn"}                     0.3 (-0.4; 1.0)       0.43     861   -1.4 ( -2.3; -0.4)     0.006    845
  CD4\<350 vs. 350≥cells/μL[\*\*\*](#nt105){ref-type="table-fn"}                    9.1 (2.8; 15.6)      0.004     949    5.7 (-0.9; 12.9)      0.09     912
  VL, cART-treated patients (pr. 10-fold)[\*\*\*](#nt105){ref-type="table-fn"}      14.7 (9.4; 20.3)    \<0.001    795    15.4 (9.9; 21.1)     \<0.001   780
  VL, for untreated patients (pr. 10-fold)[\*\*\*](#nt105){ref-type="table-fn"}     4.1 (-2.2; 10.9)      0.20     150     2.0 (-5.3; 9.9)      0.60     132
  **Lifestyle and Body Composition**                                                                                                                    
  Daily vs. no daily smoking                                                       26.4 (18.3; 35.1)    \<0.001    428    26.7 (18.6; 35.4)    \<0.001   428
  Waist circumference (cm)[\#](#nt106){ref-type="table-fn"}                         0.2 (-0.04; 0.5)      0.09     415     0.3 (0.02; 0.6)      0.03     408
  BMI \<20 vs. 20-25 (kg/m^2^)[\#\#](#nt107){ref-type="table-fn"}                   2.9 (-6.5; 13.2)      0.01     483    -0.8 (-8.8; 11.4)     0.07     408
  BMI \<20 vs. 25-30 (kg/m^2^)[\#\#](#nt107){ref-type="table-fn"}                   11.9 (1.0; 23.9)                      7.5 (-5.3; 22.0)              
  BMI \<20 vs. ≥30 (kg/m^2^)[\#\#](#nt107){ref-type="table-fn"}                    -5.8 (-17.6; 7.9)                     -6.6 (-22.4; 12.4)             
  Metabolic syndrome[\#](#nt106){ref-type="table-fn"}                               6.6 (-1.8; 15.8)      0.13     366     8.4 (0.2; 17.2)      0.04     338

All multiple analyses are adjusted for sex, age, and European descent.

\*Multiple analyses are als° adjusted for time since HIV-diagnosis.

^\*\*^Multiple analyses are also adjusted for time since HIV-diagnosis, current treatment and nadir CD4+ cell counts.

^\*\*\*^Multiple analyses are also adjusted for time since HIV-diagnosis, nadir CD4+ cell counts, current treatment, CD4+\<350 vs. ≥350 cells/μL, and log~10~(VL).

Multiple analyses are also adjusted for daily smoking.

Multiple analyses are also adjusted for daily smoking, waist circumference.

**Abbreviations:** cART: Combination antiretroviral treatment; VL: viral load; BMI: Body mass index; CI: Confidence interval.

[Table 3](#pone-0094152-t003){ref-type="table"} contains multiple errors. Please see the corrected [Table 3](#pone-0094152-t003){ref-type="table"} here.

10.1371/journal.pone.0051698.t003

###### Subgroup analyses of body composition and suPAR levels in patients with DXA scan.
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                                       Univariate       Multivariate                                       
  ------------------------------- -------------------- -------------- ----- -------------------- --------- -----
  Lean mass/h^2^ (kg/m^2^)         -1.8 (-3.4; -0.1)        0.04       283   -2.3 (-4.2; -0.4)     0.02     283
  Lean mass~leg~/h^2^ (kg/m^2^)    -9.0 (-13.0; -4.9)     \<0.001      283   -9.1 (-13.3; -4.8)   \<0.001   283
  Fat mass/h^2^ (kg/m^2^)           0.1 (-1.4; 1.6)         0.93       283    1.3 (-0.6; 3.3)      0.17     234
  Total fat%                        0.1 (-0.4; 0.5)         0.76       283    0.4 (-0.2; 1.1)      0.19     234
  Limb fat%                         0.1 (-0.3; 0.5)         0.70       283    0.4 (-0.2; 1.1)      0.20     234
  Trunk fat %/leg fat %            -3.7 (-11.7; 5.0)        0.40       283   -4.2 (-20.7; 9.6)     0.37     234

Multiple analyses of lean mass measures are adjusted for sex, age and European descent. Multiple analyses of fat mass measures are adjusted for sex, age, European descent, and daily smoking.

**Abbreviations:** CI: Confidence interval; h = height.

[Figure 2](#pone-0094152-g001){ref-type="fig"} and the associated legend are incorrect. The authors have provided a corrected version here.
